Commentary

* Author for correspondence

Departments of Pathology & Pediatrics, L235, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA and Center for Genomics & Personalized Medicine, Stanford University Medical Center, Stanford, CA, USA.

Email the corresponding author at ischrijver@stanfordmed.org

Stephen J Galli

Center for Genomics & Personalized Medicine, Stanford University Medical Center, Stanford, CA, USA and Departments of Pathology & Microbiology & Immunology, Stanford University Medical Center, Stanford, CA, USA

Search for more papers by this author

Published Online:4 May 2012https://doi.org/10.2217/pme.11.76

View article

Keywords:

References

1 Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26(10),1135–1145 (2008).
Medline CASGoogle Scholar
2 Ng SB, Turner EH, Robertson PD et al. Targeted capture and massively parallel sequencing of 12 human exomes. Nature461(7261),272–276 (2009).
Medline CASGoogle Scholar
3 Lupski JR, Reid JG, Gonzaga-Jauregui C et al. Whole-genome sequencing in a patient with charcot-marie-tooth neuropathy. N. Engl. J. Med.362(13),1181–1191 (2010).
Medline CASGoogle Scholar
4 Pleasance ED, Cheetham RK, Stephens PJ et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature463(7278),191–196 (2010).
Medline CASGoogle Scholar
5 Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Clin. Chem.55(4),641–658 (2009).
Medline CASGoogle Scholar
6 Khoury MJ, Mcbride CM, Schully SD et al. The scientific foundation for personal genomics: recommendations from a national institutes of health-centers for disease control and prevention multidisciplinary workshop. Genet. Med.11(8),559–567 (2009).
Medline CASGoogle Scholar
7 Ashley EA, Butte AJ, Wheeler MT et al. Clinical assessment incorporating a personal genome. Lancet375(9725),1525–1535 (2010).
Medline CASGoogle Scholar
8 Mcguire AL, Burke W. An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons. JAMA300(22),2669–2671 (2008).
Medline CASGoogle Scholar
9 Tucker T, Marra M, Friedman JM. Massively parallel sequencing: the next big thing in genetic medicine. Am. J. Hum. Genet.85(2),142–154 (2009).
Medline CASGoogle Scholar
10 Samani NJ, Tomaszewski M, Schunkert H. The personal genome – the future of personalised medicine? Lancet375(9725),1497–1498 (2010).
MedlineGoogle Scholar
11 Bolouri H. Computational challenges of personal genomics. Curr. Genomics9(2),80–87 (2008).
Medline CASGoogle Scholar
12 Kohane IS, Masys DR, Altman RB. The incidentalome: a threat to genomic medicine. JAMA296(2),212–215 (2006).
Medline CASGoogle Scholar
13 Ashcroft RE. Human rights and ethics in genomic research: rethinking the model. Pharmacogenomics8(4),391–395 (2007).
Google Scholar
14 Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury conference center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am. J. Clin. Pathol.135(5),668–672 (2011).
MedlineGoogle Scholar

Vol. 9, No. 3

Metrics

Downloaded 405 times

History

Published online 4 May 2012

Published in print May 2012

Information

Keywords

Financial & competing interests disclosure

SJ Galli is a member of the Board of Directors and a stock holder of Atossa Genetics, Inc., a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download

Between hype and hope: whole-genome sequencing in clinical medicine

References